According to results from the SUSTAIN trial, the addition of semaglutide, a glucagon-like peptide-1 receptor agonist, to a sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy led to significant improvements in glycemic control, as well as weight reduction, in patients with inadequately controlled type 2 diabetes.
The Food and Drug Administration (FDA) has approved an expanded indication for Soliqua 100/33 to include use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are uncontrolled on oral antidiabetic agents, in addition to those inadequately controlled on basal insulin or lixisenatide.
Tirosint-SOL (levothyroxine sodium oral solution) has been made available by IBSA Pharma for the treatment of hypothyroidism and pituitary thyrotropin suppression.
Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.
To investigate the association between this diabetes drug class and IBD risk, the study authors searched various databases for controlled clinical trials and observational studies involving DPP-4 inhibitors where IBD events were reported.
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
The FDA takes the advice of the panel into consideration when making decisions, however it is not bound by their recommendations.
An expert panel assessed 41 diets to come up with their final results, examining the evidence behind each diet’s claims, the short-term and long-term weight loss associated with the diet, how easy the diet is to follow, how well each diet conforms to current nutrition standards, and its effect on diabetes and cardiovascular disease prevention.
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women’s Health Initiative (WHI) hormone therapy trials.
